Brookfield eyes Mytrah Energy; Carlyle, Cadila team up for Bharat Serums bid

April 22, 2019 | 169 views

Canada’s Brookfield Asset Management Inc. is looking to acquire a majority stake in Mytrah Energy Ltd in a deal that could be valued as much as $1.5 billion, the Mint newspaper reported, citing three people aware of the development. Hyderabad-based Mytrah has a portfolio of 1.6 gigawatt of renewable energy projects and has been looking for an investor for almost a year. The Mint report said that the company needs to repay a loan of Rs 1,800 crore that it had taken from Piramal Group in September 2017 to buy out its private equity investors. Brookfield has so far focussed on infrastructure and real estate sectors in India, but also has a presence in the renewable energy sector thanks to its 2017 acquisition of US firm SunEdison Inc.

Spotlight

Hyphens Pharma International Ltd.

“Together We Can!” – With strong belief that Asians can contribute to healthcare of this world through passion, hard work and innovation, Hyphens Pharma International Limited, listed on Catalist, SGX-ST, is today Singapore's leading specialty pharmaceutical and consumer healthcare group. Leveraging on our diverse footprint in ASEAN countries, we have a direct presence in five ASEAN countries – Singapore (HQ), Indonesia, Malaysia, the Philippines and Vietnam, and supplemented by a marketing and distribution network covering six other markets – Bangladesh, Brunei, Cambodia, Hong Kong, Myanmar and Oman.

OTHER ARTICLES
PHARMA TECH

Tips for Managing Chronic Pain Beyond Prescription Painkillers

Article | August 9, 2022

Painkillers like Oxycontin, Percocet, and Vicodin, have been prescribed by primary physicians, surgeons, dentists, and other healthcare providers to patients suffering from varying levels of pain. Though these medications have proven to be an effective source of pain relief, they have also proven to be highly addictive. In fact, it has even been reported that there are more cases of a drug overdose and deaths from prescription painkillers than heroin or cocaine. While there are a number of factors that play into this opioid epidemic, educating doctors and patients on alternative solutions to managing chronic pain is a great place to start combatting this nationwide crisis.

Read More
PHARMA TECH

What are the advantages of PCD Pharma Company?

Article | October 6, 2022

PCD Pharma stands for propaganda distribution. A PCD company gives brand name and support to its franchises. They also provide distribution rights and monopoly rights within a particular region. If a person wants to establish their business, it is a must for them to know the pros and cons of the business to make a sound decision. Needless to mention that PCD company has a lot to contribute in the medical filed. Worldwide in a medical field, A PCD Pharma Company is playing an essential and crucial role in the rapid growth. The pharma industry is progressing t a fast pace. The company uses the latest technologies for each brand which ensures the safety of products and accepts the responsibility of human health & life by providing better outcomes. To have a drug license number and company registration, the cost to establish the company is quite cost-effective that is15000-20000rs. So this gives people a brilliant opportunity to have their unit without digging a big hole in their bank balance. Indian produces exquisite quality products, which make pharma companies a considerable success.

Read More
PHARMA TECH

WALGREEN’S IN HOT WATER OVER PHONY PHARMACIST

Article | July 20, 2022

The drugstore chain agreed to pay $7.5 million in fines after an unlicensed pharmacist at several San Francisco Bay locations illegally filled more than 700,000 prescriptions over a ten-year period. According to California prosecutors, Kim Thien Le stole license numbers from other pharmacists to fill prescriptions for Fentanyl, morphine, and other painkillers. Le pleaded guilty to multiple felony impersonation counts. Walgreen’s agreed to the settlement to avoid being charged with consumer fraud in Alameda and Santa Anna Counties. Prosecutors alleged that Walgreen’s failed to verify Le’s license and did not conduct a thorough background check. The company insisted it has taken remedial measures.

Read More

How Can Medical Cannabis Help to Manage Pain Conditions? – The Cannabis Exchange

Article | February 11, 2020

Pain management is one of the most common reasons for the use of medical cannabis products. However, despite many jurisdictions – including Canada, Germany, and the Netherlands – now allowing the prescription of medical cannabis for this purpose, there remains little ‘high-quality’ evidence to support, or oppose its efficacy. Madden et al. (2018) set out to review the evidence available in order to determine the efficacy of medical cannabis when employed in the management of various forms of musculoskeletal pain. The researchers analysed various studies that assessed the use of cannabinoids in the treatment of arthritis pain; back pain; postoperative pain; and trauma-related pain. It is estimated that up to 30% of the population may suffer from a non-cancer-related pain condition. As such a high percentage of people suffer from these conditions, the development of simple and safe therapies is an essential area of research. This is particularly important as the therapeutic options for people with chronic pain are increasingly limited.

Read More

Spotlight

Hyphens Pharma International Ltd.

“Together We Can!” – With strong belief that Asians can contribute to healthcare of this world through passion, hard work and innovation, Hyphens Pharma International Limited, listed on Catalist, SGX-ST, is today Singapore's leading specialty pharmaceutical and consumer healthcare group. Leveraging on our diverse footprint in ASEAN countries, we have a direct presence in five ASEAN countries – Singapore (HQ), Indonesia, Malaysia, the Philippines and Vietnam, and supplemented by a marketing and distribution network covering six other markets – Bangladesh, Brunei, Cambodia, Hong Kong, Myanmar and Oman.

Related News

Inside plan to grow marijuana in Uganda

monitor | April 21, 2019

Different entities and individuals are fighting over the control of Uganda’s prospective medicinal cannabis industry, with a section of government officials reportedly fronting a number of companies to cash in on the multi-billion dollar business. Several entities with connections to already established companies in Europe and North America have been lined up by different officials as the government ponders a dive into the lucrative but dicey business. There is also a fight between several entities of government on who should take the lead in directing to the different investors lining up to engage in the lucrative business estimated to be worth $3b (about Shs11.1 trillion) when it commences. Among the entities that would be involved in licensing the entire chain are the ministries of Health, Agriculture, Justice and Constitutional Affairs and Internal Affairs; the National Drug Authority (NDA) and Uganda Investment Authority (UIA). The use of cannabis for recreational purposes such as smoking remains illegal in the country. Authorities are, however, exploring its production for medical purposes subject to authorisation by relevant government bodies in line with the Narcotic Drug and Pyschotropic Substances (Control) Act 2015.

Read More

Project aims to revive natural product discovery

eurekalert | April 23, 2019

The mid-20th century was the golden age of natural product discovery. Scientists discovered ground-breaking drugs, like penicillin and tetracycline, from sources in nature. But as the search for natural products continued, pharmaceutical companies kept finding the same products over and over again. By the early 2000s, most of these companies shut down their natural product discovery programs. At the same time, the era of genomics emerged. Instead of looking for natural products, scientists were now able to use genetic information to understand how natural products were made. This brought success in discovering new natural products, but only on a very small scale. Now, a new project aims to discover new natural products on a large scale by using synthetic biology and automation.

Read More

Dr Reddy's gets Chinese regulator nod for anti-blood clotting drug

business-standard | April 23, 2019

Sources said the company got approval earlier this month for generic Clopidogrel, which is used primarily to prevent blood clotting and acts against cardiovascular problems. Hyderabad-based Dr Reddy’s Laboratories (DRL), which is betting big on the Chinese drug market, recently got an approval for a $1.6-billion anti-blood clotting drug from the Chinese regulator after an 11-year wait. Sources said the company got approval earlier this month for generic Clopidogrel, which is used primarily to prevent blood clotting and acts against cardiovascular problems. The launch of the product is still some time away. This would be DRL’s biggest product in China in terms of market potential. The drug is now undergoing generic equivalent assessment (China requires drugmakers to conduct bioequivalence studies).

Read More

Inside plan to grow marijuana in Uganda

monitor | April 21, 2019

Different entities and individuals are fighting over the control of Uganda’s prospective medicinal cannabis industry, with a section of government officials reportedly fronting a number of companies to cash in on the multi-billion dollar business. Several entities with connections to already established companies in Europe and North America have been lined up by different officials as the government ponders a dive into the lucrative but dicey business. There is also a fight between several entities of government on who should take the lead in directing to the different investors lining up to engage in the lucrative business estimated to be worth $3b (about Shs11.1 trillion) when it commences. Among the entities that would be involved in licensing the entire chain are the ministries of Health, Agriculture, Justice and Constitutional Affairs and Internal Affairs; the National Drug Authority (NDA) and Uganda Investment Authority (UIA). The use of cannabis for recreational purposes such as smoking remains illegal in the country. Authorities are, however, exploring its production for medical purposes subject to authorisation by relevant government bodies in line with the Narcotic Drug and Pyschotropic Substances (Control) Act 2015.

Read More

Project aims to revive natural product discovery

eurekalert | April 23, 2019

The mid-20th century was the golden age of natural product discovery. Scientists discovered ground-breaking drugs, like penicillin and tetracycline, from sources in nature. But as the search for natural products continued, pharmaceutical companies kept finding the same products over and over again. By the early 2000s, most of these companies shut down their natural product discovery programs. At the same time, the era of genomics emerged. Instead of looking for natural products, scientists were now able to use genetic information to understand how natural products were made. This brought success in discovering new natural products, but only on a very small scale. Now, a new project aims to discover new natural products on a large scale by using synthetic biology and automation.

Read More

Dr Reddy's gets Chinese regulator nod for anti-blood clotting drug

business-standard | April 23, 2019

Sources said the company got approval earlier this month for generic Clopidogrel, which is used primarily to prevent blood clotting and acts against cardiovascular problems. Hyderabad-based Dr Reddy’s Laboratories (DRL), which is betting big on the Chinese drug market, recently got an approval for a $1.6-billion anti-blood clotting drug from the Chinese regulator after an 11-year wait. Sources said the company got approval earlier this month for generic Clopidogrel, which is used primarily to prevent blood clotting and acts against cardiovascular problems. The launch of the product is still some time away. This would be DRL’s biggest product in China in terms of market potential. The drug is now undergoing generic equivalent assessment (China requires drugmakers to conduct bioequivalence studies).

Read More

Events